Ironwood Pharma, Forest Labs (FRX) Report Results from Additional Analyses of Phase 2b Study for Linaclotide in Patients with IBS-C
More News related to FRX
- Ironwood Pharma and Forest Labs (FRX) Announces Positive Top-Line Results for Linaclotide in Two Phase 3's
- Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation
- Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
- Trading Review for Discovery Laboratories Inc. Issued by Beacon Equity
- Deutsche Bank Upgrades Freeport-McMoRan (FCX) to Buy; More Positive on Stock After 2 Strong Quarters
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced results from additional analyses of their Phase 2b study assessing the safety and efficacy of the novel, first-in-class agent linaclotide in 419 patients with irritable bowel syndrome with constipation.
Previous analyses of these data indicated that once-daily oral dosing with linaclotide, across a range of doses, significantly improved abdominal symptoms, bowel habits, and global assessments over the 12-week treatment period. These additional analyses demonstrated that patients treated with linaclotide experienced a statistically significant improvement in abdominal symptoms, bowel habits, and global assessments within the first week of treatment. Results were presented today at the Digestive Disease Week conference being held in Chicago from May 30 through June 4, 2009. The companies also will present additional data throughout the week from studies of linaclotide in patients with IBS-C or chronic constipation.
Related Categories
Corporate NewsStocks Mentioned
+0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
